About

Compared to research and development of highly effective microbiome-based products that reactively treat adult disease, microbial-derived solutions for the pediatric setting have long been ignored. More recently however, research investigating how the early life microbiome provides a predisposition to various health outcomes in infants is seeing an injection of scientific interest and investment.

The inaugural Microbiome Movement – Maternal & Infant Health Summit has been established to improve your understanding of the fundamental maternal-infant microbiome mechanisms of action and advance translation of this causality into evidence-based and clinically validated therapeutic, nutritional and preventative solutions that will configure healthy foundations of the microbiome within the first 1000 days of life.

This first-of-its-kind event is your opportunity to learn from the expertise of key opinion leaders from large pharma, biotech and academic research institutes presenting the latest case studies and in-depth discussion on key topics including:

• Discovering the causal relationships between the maternal-infant microbiome and disease onset
• Exploring different therapeutic products that restore the infant microbiome, as well as treat and prevent disease
• Discussing study design for investigation of the microbiome in maternal and pediatric settings
• Understanding the role of the maternal microbiome in preterm birth and infant health outcomes
• Optimizing –omics and realizing how to integrate these data with novel pre-clinical modelling to generate clinically meaningful results
• Explaining regulatory processes for IND-approved products targeting maternal and infant populations
• Addressing public health, economic and educational considerations for commercializing microbiome-based products for mothers and infants

There is no question that the pre-, peri- and postnatal maternal and infant microbiomes are critical windows of opportunity, that need to be acted upon today.

Join us to unlock the therapeutic potential of the maternal-infant microbiome and proactively contribute to healthier clinical outcomes in new-borns brought into the world tomorrow.